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RECEIVER OPERATOR CHARACTERISTICS OF THE SYSMEX HPC MEA-
SUREMENT USED TO INITIATE APHERESIS OF BLOOD HEMATOPOIETIC
PROGENITOR CELLS
Hamilton, E.S.1, Flowers, C.R.2, Vaughn, M.L.1, Minerley, M.1,
Waller, E.K.2 1Emory Healthcare Transfusion Medicine Program,
Emory University, Atlanta, GA; 2Winship Cancer Institute, Emory
University, Atlanta, GA.
Background: Hematopoietic progenitor cells (HPC) can be
mobilized into the peripheral blood by the administration of
G-CSF and/or GM-CSF and collected by apheresis for patients
who are candidates for high dose chemotherapy and autologous
stem cell transplantation. The initiation of apheresis is com-
monly based upon the number of CD34 cells/L in the blood,
using a ﬂow cytometric assay that typically requires 2 hours for
sample preparation, acquisition, and reporting results. The
availability of a new technology for rapidly measuring the con-
tent of hematopoietic progenitor cells in blood samples based
upon size and impedance (Sysmex™) prompted an evaluation of
how this method compares to the CD34 ﬂow cytometric assay.
Methods: Prospective analysis was performed on 100 samples
of cytokine mobilized peripheral blood from adult patients (ages
27-73) scheduled for collection of autologous HPC by aphere-
sis. The HPC content was assayed using the Sysmex™
XE2100L (performed by the apheresis staff), and by the clinical
lab using a dual platform BD FACScaliber™ and a modiﬁed
ISHAGE protocol. The study population consisted of lym-
phoma (n  32), multiple myeloma (n  27), Hodgkin’s disease
(n  9), and one patient each with CLL, germ cell cancer, and
amyloidosis. Results: The mean number of CD34 cells/L
determined using ﬂow cytometry was 57.6/L compared to
102.6/L using the Sysmex™, with a correlation coefﬁcient of
0.69. Of 71 patients being considered for apheresis, a mean
number of 14.7  106CD34 cells/kg were successfully col-
lected from 62 patients (87%). An analysis of the receiver
operating characteristics of the Sysmex assay, using the ﬂow
cytometric CD34 cell assay as a “gold-standard,” revealed that
initiation of apheresis when the Sysmex HPC threshold was
31 cells/L optimized the sensitivity and speciﬁcity of the test,
and was the best predictor of when patients should begin
apheresis collection (Table 1). The positive predictive value for
a Sysmex™ HPC result of 31/L was 80% (CD34 cell
counts of 	20/L); the negative predictive value for a Sysmex™
HPC of 31 cells/L was 88% (12% had CD34 cell counts
of 	 20/L). Conclusions: Use of the Sysmex™ method for
estimating HPC cell content of the peripheral blood is fast and
reliable, with excellent sensitivity and speciﬁcity compared to
ﬂow cytometry. Using the Sysmex™ HPC result to initiate
apheresis has reduced the average apheresis collection start time
more than an hour (Table 1).
Table 1. ROC of SysmexTM HPC Using CD34 	 20/L as the
Standard
HPC/L Sensitivity Specificity
>10 97.3% 52.8%
>20 91.9% 69.8%
>30 83.8% 84.9%
>40 78.4% 88.7%
>50 67.6% 92.5%
>60 62.2% 94.3%
>70 59.5% 94.3%
>80 56.8% 94.3%
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HIGH DOSE THERAPY VERSUS ORAL MAINTENANCE: RESULT OF HD-
CWS 96 STUDY FOR TREATMENT OF PATIENTS WITH METASTASIZED
SOFT TISSUE SARCOMA (STS)
Klingebiel, T.E.1, Boos, J.2, Hallmen, E.3, Beske, F.1, Treuner, J.2,
Koscielniak, E.2 1University Children’s Hospital, Frankfurt, Germany;
2University Children’s Hospital, Muenster, Germany; 3Olgahospital,
Stuttgart, Germany.
Objectives: We studied the efﬁcacy of high dose (HD) versus an
oral maintenance treatment (OMT) in patients with STS stage IV.
Methods: HD consisted of a tandem cycle of thiotepa (600 mg/
m2)  cyclophosphamide (4500 mg/m2) and melphalan (120 mg/
m2)  etoposide (1800 mg/m2). This treatment was optionally
compared with each 4 OMT cycles consisting of trofosfamide (10
days 275 mg/m2/d)  etoposide (10 days 225 mg/m2/d) and
trofosfamide (10 days 275 mg/m2/d)  idarubicin (10 days 45
mg/m2). Both groups were pretreated with the CEVAIE therapy
(HD 7, OMT 9 cycles) consisting of carboplatin, etoposide, vin-
cristine, actinomycin D, ifosfamide, and epirubicin. Results:Over-
all 753 patients were registered in CWS 96. From those 96 patients
fulﬁlled study inclusion criteria (primary stage IV, 22 years, and
intent to treat with study therapy). 45 were treated with HD, 51
with OMT. Whereas the study was not randomized, in the OMT
and HD groups the main risk parameters were equally distributed.
In the OMT group 15/51 (29%) fulﬁlled highest risk criteria (age
10 years and bone or bone marrow involvement), in the HD
group 16/45 (35%) respectively. However, in the HD-group 11/45
were alive at a median observation time of 24.6 months (24.4%), in
contrast to 26/51 OMT patients (50.9.%). Kaplan-Meier analysis
demonstrates an overall survival for the whole group of 0.27 (OMT
group: 0.31, HD group 0.20, log rank 0.0349). The proportional
hazard analysis for patients with rhabdomyosarcoma only (77.1%
of all patients) demonstrates an independent beneﬁt of oral main-
tenance treatment on outcome. Conclusions: Oral maintenance
therapy instead of tandem high dose therapy in patients with soft
tissue sarcoma stage IV seems to be a promising option for patients
with rhabdomyosarcoma.
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TARGETED RADIOTHERAPY IN THE CONDITIONING PRIOR TO HAEMA-
TOPOIETIC STEM CELL TRANSPLANTATION: RESULTS OF A PHASE I
TRIAL USING AN YTTRIUM-90-LABELLED ANTI-CD66 MURINE MONO-
CLONAL ANTIBODY DEMONSTRATING CONSISTENTLY HIGH BM UP-
TAKE
Orchard, K.H.1, Cooper, M.2, Lewington, V.3, Tristam, M.3,
Zivanovic, M.3, Thom, J.3, Quadri, S.4, Richardson, D.1, Causer, L.3,
Johnson, P.5 1Department of Haematology, Southampton, Hants, United
Kingdom; 2Department of Nuclear Medicine, St. Barthlemew’s Hospital,
London, United Kingdom; 3Department of Nuclear Medicine, SUHT,
Southampton, Hants, United Kingdom; 4National Institute for Health,
Bethesda, MD; 5Division of Cancer Sciences, SUHT, Southampton,
Hants, United Kingdom.
We report the results of a phase I clinical trial using an yttri-
um-90 (Y-90) radiolabelled anti-CD66 IgG1 murine monoclonal
antibody (TheraPharm GmbH) with conditioning therapy for pa-
tients receiving either an autologous or reduced intensity (RIC)
allogeneic stem cell transplant (SCT) for myeloma or AML. This
was a radiation dose escalation study with ﬁve patients at each
radiation dose level of 5, 10, 25 and 37.5 MBq/kilogram lean body
weight of recipient. Patients initially received indium-111-labelled
anti-CD66 for biodistribution and dosimetry. Patient Character-
istics: Ages 21-67 yrs (mean 56 yrs); 16 male, 4 female; disease
indication for transplant: myeloma 18, poor risk AML 2. Autolo-
gous transplant 16; RIC-allogeneic 4. Patients received the thera-
peutic dose of radiation on day 14, for autologous SCT they also
received melphalan 200 mg/m2 on day 2; allogeneic SCT pa-
tients received a combination of ﬂudarabine, melphalan and CAM-
PATH from day 8. Results: Excellent bone marrow targeting
was seen in all patients with a 2-10 fold excess of radiation deliv-
Oral Presentations
10
